Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Compensated chronic hepatitis B patient~* Presence of serum HBsAg for more than 6 months.~* Presence of HBeAg for more than 1 month with compensated liver disease~* Confirmation of YMDD mutants (M552V, M552I and its related double mutant at L528M) by genotyping of the YMDD motif using line probe assay (INNO-LiPA HBV DR assay)~* Screening HBV DNA value higher than or equal to 1,000,000 copies/mL (measured by the COBAS Amplicor HBV Monitor™ assay)~* Screening ALT value between 1.5 and 10 x ULN~Exclusion Criteria:~* Co-infection with hepatitis C or D virus (HCV or HDV) or HIV~* Pregnancy or breast-feeding~* Previous treatment with nucleoside analogue or any other treatment for HBV except for lamivudine within 6 months prior to study entry~* Treatment with immunomodulatory agent or corticosteroids within 6 months prior to study entry.~* De-compensated liver disease~* Screening alpha-fetoprotein (AFP) value \> 20 ng/mL, and a follow-up ultrasonography performed prior to baseline shows findings indicative of HCC.~* Presence of anti-HBs at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LB80380 30mg (Type: EXPERIMENTAL): LB80380 30mg
- LB80380 60mg (Type: EXPERIMENTAL): LB80380 60mg
- LB80380 90mg, (Type: EXPERIMENTAL): LB80380 90mg
- LB80380 150mg (Type: EXPERIMENTAL): LB80380 150mg
- LB80380 240mg (Type: EXPERIMENTAL): LB80380 240mg

Based on this trial design, predict the completion outcome and termination type (if applicable).